Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Dec;78(11):1507–1513. doi: 10.1038/bjc.1998.714

Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence.

T Jahkola 1, T Toivonen 1, I Virtanen 1, K von Smitten 1, S Nordling 1, K von Boguslawski 1, C Haglund 1, H Nevanlinna 1, C Blomqvist 1
PMCID: PMC2063217  PMID: 9836485

Abstract

We have recently demonstrated an association between distant metastasis and the expression of the extracellular matrix glycoprotein tenascin-C (Tn-C) in the invasion border of small axillary node-negative breast carcinomas. Our purpose was to assess the relationship between the expression of Tn-C in the tumour invasion border and several histopathological and biological variables and to compare their usefulness in predicting local and distant disease recurrences. The original patient group consisted of 143 women with axillary node-negative breast cancer (one bilateral) treated with breast-conserving surgery and post-operative radiotherapy, and followed for a median of 8 years. Because of the small number of recurrences an additional group of 15 similarly treated women with recurrent breast cancer was also studied. The size of the tumour, its histology, including a possible intraductal component, and grade were re-evaluated. The expression of erbB-2, p53, Ki-67 and Tn-C was evaluated by immunohistochemistry. Ploidy and S-phase fraction (SPF) were assessed by flow cytometry. The only statistically significant prognostic factor for local recurrence was Tn-C expression in the invasion border. For metastasis Ki-67 positivity, tumour size and Tn-C expression in the invasion border were statistically significant, but Ki-67 positivity was the only independent prognostic factor. Tn-C expression in the invasion border was associated with a higher proliferation rate measured by Ki-67 and SPF, which is consistent with the suggested growth-promoting activity of Tn-C. Tn-C may be a useful marker in selecting patients for adjuvant therapies to reduce the rate of both local and distant cancer recurrences.

Full text

PDF
1507

Images in this article

1509Figure 1
on p.1509

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Borger J., Kemperman H., Hart A., Peterse H., van Dongen J., Bartelink H. Risk factors in breast-conservation therapy. J Clin Oncol. 1994 Apr;12(4):653–660. doi: 10.1200/JCO.1994.12.4.653. [DOI] [PubMed] [Google Scholar]
  3. Boyages J., Recht A., Connolly J. L., Schnitt S. J., Gelman R., Kooy H., Love S., Osteen R. T., Cady B., Silver B. Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. Radiother Oncol. 1990 Sep;19(1):29–41. doi: 10.1016/0167-8140(90)90163-q. [DOI] [PubMed] [Google Scholar]
  4. Clark G. M., Dressler L. G., Owens M. A., Pounds G., Oldaker T., McGuire W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989 Mar 9;320(10):627–633. doi: 10.1056/NEJM198903093201003. [DOI] [PubMed] [Google Scholar]
  5. Clark R. M., McCulloch P. B., Levine M. N., Lipa M., Wilkinson R. H., Mahoney L. J., Basrur V. R., Nair B. D., McDermot R. S., Wong C. S. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst. 1992 May 6;84(9):683–689. doi: 10.1093/jnci/84.9.683. [DOI] [PubMed] [Google Scholar]
  6. Ferguson J. E., Schor A. M., Howell A., Ferguson M. W. Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. Differentiation. 1990 Feb;42(3):199–207. doi: 10.1111/j.1432-0436.1990.tb00762.x. [DOI] [PubMed] [Google Scholar]
  7. Fisher B., Anderson S., Redmond C. K., Wolmark N., Wickerham D. L., Cronin W. M. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995 Nov 30;333(22):1456–1461. doi: 10.1056/NEJM199511303332203. [DOI] [PubMed] [Google Scholar]
  8. Fisher E. R., Costantino J., Fisher B., Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer. 1993 Mar 15;71(6 Suppl):2141–2150. doi: 10.1002/1097-0142(19930315)71:6+<2141::aid-cncr2820711603>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  9. Gage I., Schnitt S. J., Nixon A. J., Silver B., Recht A., Troyan S. L., Eberlein T., Love S. M., Gelman R., Harris J. R. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer. 1996 Nov 1;78(9):1921–1928. doi: 10.1002/(sici)1097-0142(19961101)78:9<1921::aid-cncr12>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  10. Gelber R. D., Goldhirsch A. Radiotherapy to the conserved breast: is it avoidable if the cancer is small? J Natl Cancer Inst. 1994 May 4;86(9):652–654. doi: 10.1093/jnci/86.9.652. [DOI] [PubMed] [Google Scholar]
  11. Haffty B. G., Fischer D., Rose M., Beinfield M., McKhann C. Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data. J Clin Oncol. 1991 Jun;9(6):997–1003. doi: 10.1200/JCO.1991.9.6.997. [DOI] [PubMed] [Google Scholar]
  12. Hedley D. W., Friedlander M. L., Taylor I. W., Rugg C. A., Musgrove E. A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983 Nov;31(11):1333–1335. doi: 10.1177/31.11.6619538. [DOI] [PubMed] [Google Scholar]
  13. Holland R., Connolly J. L., Gelman R., Mravunac M., Hendriks J. H., Verbeek A. L., Schnitt S. J., Silver B., Boyages J., Harris J. R. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol. 1990 Jan;8(1):113–118. doi: 10.1200/JCO.1990.8.1.113. [DOI] [PubMed] [Google Scholar]
  14. Howeedy A. A., Virtanen I., Laitinen L., Gould N. S., Koukoulis G. K., Gould V. E. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Invest. 1990 Dec;63(6):798–806. [PubMed] [Google Scholar]
  15. Huuhtanen R. L., Blomqvist C. P., Wiklund T. A., Virolainen M. J., Elomaa A. I., Pan Y., Tribukait B. S-phase fraction of 155 soft tissue sarcomas: correlation with clinical outcome. Cancer. 1996 May 1;77(9):1815–1822. doi: 10.1002/(SICI)1097-0142(19960501)77:9<1815::AID-CNCR9>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  16. Ishihara A., Yoshida T., Tamaki H., Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res. 1995 Sep;1(9):1035–1041. [PubMed] [Google Scholar]
  17. Jahkola T., Toivonen T., von Smitten K., Blomqvist C., Virtanen I. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer. 1996 Dec 20;69(6):445–447. doi: 10.1002/(SICI)1097-0215(19961220)69:6<445::AID-IJC4>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  18. Jones P. L., Cowan K. N., Rabinovitch M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol. 1997 Apr;150(4):1349–1360. [PMC free article] [PubMed] [Google Scholar]
  19. Lightner V. A., Marks J. R., McCachren S. S. Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. Exp Cell Res. 1994 Feb;210(2):177–184. doi: 10.1006/excr.1994.1027. [DOI] [PubMed] [Google Scholar]
  20. Liljegren G., Holmberg L., Adami H. O., Westman G., Graffman S., Bergh J. Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group. J Natl Cancer Inst. 1994 May 4;86(9):717–722. doi: 10.1093/jnci/86.9.717. [DOI] [PubMed] [Google Scholar]
  21. Mansour E. G., Ravdin P. M., Dressler L. Prognostic factors in early breast carcinoma. Cancer. 1994 Jul 1;74(1 Suppl):381–400. doi: 10.1002/cncr.2820741326. [DOI] [PubMed] [Google Scholar]
  22. Morrow M., Harris J. R., Schnitt S. J. Local control following breast-conserving surgery for invasive cancer: results of clinical trials. J Natl Cancer Inst. 1995 Nov 15;87(22):1669–1673. doi: 10.1093/jnci/87.22.1669. [DOI] [PubMed] [Google Scholar]
  23. Ravdin P. M., Chamness G. C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. Gene. 1995 Jun 14;159(1):19–27. doi: 10.1016/0378-1119(94)00866-q. [DOI] [PubMed] [Google Scholar]
  24. Rosen P. P., Lesser M. L., Arroyo C. D., Cranor M., Borgen P., Norton L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol. 1995 Apr;13(4):821–830. doi: 10.1200/JCO.1995.13.4.821. [DOI] [PubMed] [Google Scholar]
  25. Sakakura T., Ishihara A., Yatani R. Tenascin in mammary gland development: from embryogenesis to carcinogenesis. Cancer Treat Res. 1991;53:383–400. doi: 10.1007/978-1-4615-3940-7_18. [DOI] [PubMed] [Google Scholar]
  26. Schnitt S. J., Connolly J. L., Khettry U., Mazoujian G., Brenner M., Silver B., Recht A., Beadle G., Harris J. R. Pathologic findings on re-excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy. Cancer. 1987 Feb 15;59(4):675–681. doi: 10.1002/1097-0142(19870215)59:4<675::aid-cncr2820590402>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  27. Schnitt S. J., Hayman J., Gelman R., Eberlein T. J., Love S. M., Mayzel K., Osteen R. T., Nixon A. J., Pierce S., Connolly J. L. A prospective study of conservative surgery alone in the treatment of selected patients with stage I breast cancer. Cancer. 1996 Mar 15;77(6):1094–1100. [PubMed] [Google Scholar]
  28. Silvestrini R., Benini E., Daidone M. G., Veneroni S., Boracchi P., Cappelletti V., Di Fronzo G., Veronesi U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1993 Jun 16;85(12):965–970. doi: 10.1093/jnci/85.12.965. [DOI] [PubMed] [Google Scholar]
  29. Silvestrini R., Daidone M. G., Luisi A., Boracchi P., Mezzetti M., Di Fronzo G., Andreola S., Salvadori B., Veronesi U. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol. 1995 Mar;13(3):697–704. doi: 10.1200/JCO.1995.13.3.697. [DOI] [PubMed] [Google Scholar]
  30. Tiitta O., Wahlström T., Paavonen J., Linnala A., Sharma S., Gould V. E., Virtanen I. Enhanced tenascin expression in cervical and vulvar koilocytotic lesions. Am J Pathol. 1992 Oct;141(4):907–913. [PMC free article] [PubMed] [Google Scholar]
  31. Veronesi U., Marubini E., Del Vecchio M., Manzari A., Andreola S., Greco M., Luini A., Merson M., Saccozzi R., Rilke F. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 1995 Jan 4;87(1):19–27. doi: 10.1093/jnci/87.1.19. [DOI] [PubMed] [Google Scholar]
  32. Victorzon M., Roberts P. J., Haglund C., von Boguslawsky K., Nordling S. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Oncology. 1996 May-Jun;53(3):182–191. doi: 10.1159/000227558. [DOI] [PubMed] [Google Scholar]
  33. Yoshida T., Ishihara A., Hirokawa Y., Kusakabe M., Sakakura T. Tenascin in breast cancer development--is epithelial tenascin a marker for poor prognosis? Cancer Lett. 1995 Mar 23;90(1):65–73. doi: 10.1016/0304-3835(94)03679-d. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES